This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Aetiology of hypercalcaemia

Authoring team

The common causes of hypercalcaemia which accounts for about 90% of cases are due to primary hyperparathyroidism and malignancy:

  • primary hyperparathyroidism – commonest cause in the community (1), accounts for 80% of cases and is more important in the young
  • malignancy accounts for 20-30% of cases (1) and is frequently accompanied by hypoalbuminaemia:
    • suggested by rapidly increasing hypercalcaemia (1)
    • metastases with osteolytic deposits e.g. breast
    • osteoclast activating factors e.g. multiple myeloma
    • ectopic parathyroid hormone like peptide e.g. hypernephroma, ovarian tumour, bronchial carcinoma
    • 10-15% of hypercalcaemia caused by malignancy have associated hyperparathyroidism (2)

Rarer causes of hypercalcaemia include:

  • increased extrarenal synthesis of calcitriol in chronic granulomatous disease:
    • sarcoidosis
    • pulmonary tuberculosis
    • berylliosis
  • Addison's disease
  • Paget's disease with bed rest
  • immobilisation - especially in adolescence when bone turnover is increased
  • vitamin A and/or D toxicity
  • drugs:
    • thiazide diuretics
    • lithium
  • thyrotoxicosis:
    • usually mild and accompanied by hypercalciuria
    • due to increased bone turnover
  • familial hypocalciuric hypercalcaemia
  • tertiary hyperparathyroidism
  • milk alkali syndrome
  • multiple endocrine neoplasia (MEN) (2,3)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.